Literature DB >> 17209042

Biochemical and functional analyses of the human Toll-like receptor 3 ectodomain.

C T Ranjith-Kumar1, William Miller, Jin Xiong, William K Russell, Roberta Lamb, Jonathan Santos, Karen E Duffy, Larissa Cleveland, Mary Park, Kanchan Bhardwaj, Zhaoxiang Wu, David H Russell, Robert T Sarisky, M Lamine Mbow, C Cheng Kao.   

Abstract

The structure of the human Toll-like receptor 3 (TLR3) ectodomain (ECD) was recently solved by x-ray crystallography, leading to a number of models concerning TLR3 function (Choe, J., Kelker, M. S., and Wilson, I. A. (2005) Science 309, 581-585; Bell, J. K., Botos, I., Hall, P. R., Askins, J., Shiloach, J., Segal, D. M., and Davies, D. R. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 10976-10980) The structure revealed four pairs of cysteines that are putatively involved in disulfide bond formation, several residues that are predicted to be involved in dimerization between ECD subunits, and surfaces that could bind to poly(I:C). In addition, there are two loops that protrude from the central solenoid structure of the protein. We examined the recombinant TLR3 ECD for disulfide bond formation, poly(I:C) binding, and protein-protein interaction. We also made over 80 mutations in the residues that could affect these features in the full-length TLR3 and examined their effects in TLR3-mediated NF-kappaB activation. A number of mutations that affected TLR3 activity also affected the ability to act as dominant negative inhibitors of wild type TLR3. Loss of putative RNA binding did not necessarily affect dominant negative activity. All of the results support a model where a dimer of TLR3 is the form that binds RNA and activates signal transduction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17209042     DOI: 10.1074/jbc.M610946200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Does toll-like receptor-3 (TLR-3) have any role in Indian AMD phenotype?

Authors:  Neel Kamal Sharma; Kaushal Sharma; Amod Gupta; Sudesh Prabhakar; Ramandeep Singh; Pawan Kumar Gupta; Akshay Anand
Journal:  Mol Cell Biochem       Date:  2014-03-30       Impact factor: 3.396

2.  The TLR3 signaling complex forms by cooperative receptor dimerization.

Authors:  Joshua N Leonard; Rodolfo Ghirlando; Janine Askins; Jessica K Bell; David H Margulies; David R Davies; David M Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-02       Impact factor: 11.205

3.  A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy.

Authors:  Carlos Gorbea; Kimberly A Makar; Matthias Pauschinger; Gregory Pratt; Jeathrina L F Bersola; Jacquelin Varela; Ryan M David; Lori Banks; Chien-Hua Huang; Hua Li; Heinz-Peter Schultheiss; Jeffrey A Towbin; Jesús G Vallejo; Neil E Bowles
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

Review 4.  TLR3 immunity to infection in mice and humans.

Authors:  Shen-Ying Zhang; Melina Herman; Michael J Ciancanelli; Rebeca Pérez de Diego; Vanessa Sancho-Shimizu; Laurent Abel; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2013-01-03       Impact factor: 7.486

5.  Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects).

Authors:  Cordula Weber; Christian Müller; Anja Podszuweit; Carmen Montino; Jörg Vollmer; Alexandra Forsbach
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

6.  Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3.

Authors:  Mark E Kleinman; Hiroki Kaneko; Won Gil Cho; Sami Dridi; Benjamin J Fowler; Alexander D Blandford; Romulo J C Albuquerque; Yoshio Hirano; Hiroko Terasaki; Mineo Kondo; Takashi Fujita; Balamurali K Ambati; Valeria Tarallo; Bradley D Gelfand; Sasha Bogdanovich; Judit Z Baffi; Jayakrishna Ambati
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

7.  Identification and characterization of poly(I:C)-induced molecular responses attenuated by nicotine in mouse macrophages.

Authors:  Wen-Yan Cui; Shufang Zhao; Renata Polanowska-Grabowska; Ju Wang; Jinxue Wei; Bhagirathi Dash; Sulie L Chang; Jeffrey J Saucerman; Jun Gu; Ming D Li
Journal:  Mol Pharmacol       Date:  2012-10-01       Impact factor: 4.436

8.  Dimerization of Toll-like receptor 3 (TLR3) is required for ligand binding.

Authors:  Yan Wang; Lin Liu; David R Davies; David M Segal
Journal:  J Biol Chem       Date:  2010-09-22       Impact factor: 5.157

9.  Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth.

Authors:  Won Gil Cho; Romulo J C Albuquerque; Mark E Kleinman; Valeria Tarallo; Adelaide Greco; Miho Nozaki; Martha G Green; Judit Z Baffi; Balamurali K Ambati; Massimo De Falco; Jonathan S Alexander; Arturo Brunetti; Sandro De Falco; Jayakrishna Ambati
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

10.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.

Authors:  Mark E Kleinman; Kiyoshi Yamada; Atsunobu Takeda; Vasu Chandrasekaran; Miho Nozaki; Judit Z Baffi; Romulo J C Albuquerque; Satoshi Yamasaki; Masahiro Itaya; Yuzhen Pan; Binoy Appukuttan; Daniel Gibbs; Zhenglin Yang; Katalin Karikó; Balamurali K Ambati; Traci A Wilgus; Luisa A DiPietro; Eiji Sakurai; Kang Zhang; Justine R Smith; Ethan W Taylor; Jayakrishna Ambati
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.